University of Texas MD Anderson Cancer Center

OpenWorks @ MD Anderson
OncoLog MD Anderson's Report to Physicians

Research Medical Library

1990

Oncolog, Volume 35, Number 01, January-March 1990
Staff
The University of Texas MD Anderson Cancer Center

Follow this and additional works at: https://openworks.mdanderson.org/oncolog
Part of the History of Science, Technology, and Medicine Commons, and the Oncology Commons

Recommended Citation
Staff, "Oncolog, Volume 35, Number 01, January-March 1990" (1990). OncoLog MD Anderson's Report to
Physicians. 33.
https://openworks.mdanderson.org/oncolog/33

This Newsletter is brought to you for free and open access by the Research Medical Library at OpenWorks @ MD
Anderson. It has been accepted for inclusion in OncoLog MD Anderson's Report to Physicians by an authorized
administrator of OpenWorks @ MD Anderson. For more information, please contact rml-help@mdanderson.org.

January-March 1990

Volume 35, Number 1

ONCOLOG
Is Malpractice Litigation Undermining
Informed Consent?
In a society willing to assume
no risk, a good lawyer can turn
success into failure. Consider
this: Your patient has a potentially fatal cancer. His only
hope is aggressive radiotherapy.
He goes through the treatment
and is cured, but necrosis of
the jawbone caused by the
radiation leaves him with a perLester J. Peters
manent disability. He sues you
for negligence. Next time you have a similar case, would
you suggest the therapy that offers the best chance of cure,
knowing that the likely sequelae may land you in court?
Lester Peters, M.D ., feels that many physicians having
faced that scenario are choosing to treat less aggressively.
The unfortunate consequence is that true informed consent is being subverted because physicians are fearful of
potential litigation. Physicians are more likely to be sued
for a severe, debilitating side effect of aggressive treatment
than for the death of a patient, according to Peters, head
of the Division of Radiotherapy at the M. D. Anderson
Cancer Center.
It sounds irrational, but "it's much easier to convince
a jury that a severe treatment side effect is the fault of
the doctor than it is to convince them that someone dying
of cancer is the fault of the doctor," Peters said. Occasionally, in the process of saving a patient's life, severe normal
tissue injury may be unavoidable, and whereas the
physician considers the therapy a success, a patient may
view the side effect as a failure. And though such cases
are few, the specter of malpractice suits is sufficient to
make some physicians reevaluate whether to propose
aggressive therapy.

Fear of Litigation Should Be Irrelevant
To Peters, this reluctance, though certainly understandable, should be irrelevant in medical decision making
because the fundamental concern is curing the patient.
Patients must retain the option of choosing the therapy
that provides the highest chance of cure, and to do so they
must be adequately informed. "No one wants to be sued,
but it's not right to avoid it at all costs . You're not doing
your current patients a service by cutting down on potentially curative treatment just because someone in the past

has sued you," Peters said. "Most cancers require intensive
treatment to maximize the chance for cure, so unless the
patient specifically desires less aggressive treatment, avoiding the possibility of all severe sequelae should not be the
primary concern of the physician. Too little treatment
carries the worst possible toxicity: failure to cure the cancer."
Peters is by no means an advocate of ultraaggressive
therapy regardless of outcome. Aggressiveness should be
continued on page 2
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weighed against the gravity of the disease and the consequences of inadequate treatment. "If increasing the dose
provides a small increase in tumor control but a very great
risk of a severe complication (e.g., spinal necrosis), you
end up losing more than you gain," he said.
But Peters insists that, at the very least, the patient
should be made aware of the relative risks and benefits of
the entire spectrum of therapy. "Unless you involve the
patient in the decision-making process, you may not be
giving him the treatment he really wants," he said. "It's
not necessarily true that every patient wants the same
intensity of treatment. Some personalities say 'damn the
risks; I want the most intensive treatment,' whereas others
are afraid of taking that risk. I think we owe it to them to
respect those wishes."

radiotherapy half-way through in order to allow acute side
effects to resolve, after which treatment is resumed. This
is often perceived as necessary because many patients
experience a lot of discomfort during treatment. But there
is overwhelming evidence that interrupting treatment
significantly reduces the chance for cure, because during
the rest period the tumor resumes growth. Since the data
are so compelling, we feel strongly that treatment should
never be interrupted except under extreme conditions ."
Peters feels that the key to ensuring that patients continue uninterrupted treatment is to be quite clear as to the
discomfort they undoubtedly will have and to inform them
of the measures that can be taken to relieve their discomfort. "We also tell them when the pain will reach a plateau,
what side effects will heal, and what effects are irreversible.
We let them know that we'll give them all the support we
can and special foods to make things easier, but they'll
have to weather the pain if they want to maximize their
chances for cure."

Treatment Information Should Be Conveyed
in Understandable Terms
Physicians cannot go into all the ramifications of
treatment, and explaining the intricacies of clinical and
laboratory data may end up only confusing the patient.
But Peters insists that, at the very least, the results of
relevant research can be briefly presented and easily
understood by most patients.
"We don't say, 'your chances of cure are 74% if treated
this way and 63% if treated this way.' As far as the individual is concerned, he is either cured or not; he either gets a
complication or he doesn't. You can't be 74% cured, so we
tell him that with a disease like his about three-quarters of
the patients will be cured if they go through the treatment. We can't say whether he's going to be in the
fortunate three-quarters, but we can say that a particular
treatment will maximize his chances of being cured."
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Figure l. Hypothetical dose-response relationships for tumor control probability (TCP) and normal tissue
complication probability (NTCP) to illustrate the concept of "tolerance." The therapeutic ratio is "favorable"
in that the TCP curve is displaced to the left of the NTCP curve. Dose Aeffectively ovoids risk of injury to
normal tissue, but the probability of tumor control is small. But by accepting a small risk of normal tissue
injury, i.e., dose B, the TCP is significantly improved. Further dose increase dose above Bmight be desirable
but is certainly not justified above C, where NTCP increases more rapidly than TCP. Although the phrase
"normal tissue tolerance" is widely used, the real limit to radiation therapy is the "tolerance" of a certain risk
of injury by on adequately informed patient and his physician.

Awareness of Options Affects Patient's Choice
In general, for consent to be truly "informed," the
patient must be apprised of five points, according to
Peters: First, the probability of cure (or local control) of
the cancer with the proposed treatment. Second, the
probability of cure with either less intensive or more
intensive regimens. Third, the consequences if the tumor
is not controlled. Fourth, the nature of acute side effects,
such as intensity, time of onset, and duration, and the
available measures to ameliorate them. And fifth, the probability of late treatment-related complications.

As an example of the need for comprehensive patient
education, Peters points to his own work in treating head
and neck patients with radiotherapy. "It is quite common
in the radiotherapy community at large to interrupt
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The patient should also be apprised of the availability
and efficacy of "salvage" therapy in the event that the
initial treatment is unsuccessful. If effective salvage therapy
is available, the patient may opt for less aggressive initial
treatment. Alternatively, if salvage therapy is unavailable or
of limited efficacy (as is often the case), most patients will
choose to "go for broke" with their initial treatment,
Peters said.
" In most cases, when our goal is cure, it's simply
illogical to reduce the toxicity of the initial treatment,
since the patient may have to face higher morbidity during
salvage therapy," Peters said.
The degree to which a physician discusses each of these
points is dictated not only by the availability of time and
resources but also by the severity of the case. "You have to
talk to the patient in great depth when the stakes are
extremely high," Peters said. "For instance, a couple of
years ago we saw a young patient with a noncancerous
tumor in the base of the skull. The tumor had destroyed
part of the vertebral column, but there was no way to
remove the tumor surgically. Irradiation of the spinal cord
was unavoidable, so we had to talk to him and his parents
at great length as to where we wanted to aim the treatment and how much of a risk we wanted to take, since it
was possible that radiation-induced spinal necrosis would
paralyze him. We spent a long time discussing the pros
and cons of different levels of treatment before agreeing
upon a mutually acceptable point to aim at."

been out of training for 20 years, there was about a 50 /50
chance of being sued. And of the ones being sued ( regardless of outcome), one-third said that they treat people less
aggressively now than they did before they were sued."
This reluctance to treat aggressively is not limited to
experienced doctors. Peters has found that a defensive
attitude is becoming more common among residents in
training. "I'm on the examining board for certification in
radiation oncology, and I try to present a case to the
students to see if they would be prepared to risk a major
complication in order to save a patient's life. It's depressing to see how many of them won't take the slightest risk,
and when you ask them why, they'll say they don't want to
be sued. This attitude is most unfair to the majority of
patients who will not sue you but want to get the best
available treatment."

Community Standard of Treatment Intensity
Is Lowering
As a result of these changing attitudes, the acceptable
level of "standard" treatment is being reduced. Ironically,
this reduction may only exacerbate the current excesses of
litigation. "When everyone starts acting defensively, the
community standard of care, in terms of 'aggressiveness,'
gets pushed downward, and so one who is acting reasonably in absolute terms can be judged to be exceeding
community standards. This is unfortunate because the
question of whether a physician conformed to community
standards is often asked when determining negligence.
That's a very serious problem. I recently reviewed a case
in which a doctor was being sued for a treatment complication. Expert witnesses said that the treatment given
would have been perfectly acceptable 10 years ago but did
not now meet prevailing standards. What they were really
saying was that the standard of taking a modest risk to
maximize the chance of cure has changed, and that we live
in a society that wants no risk. I don't subscribe to that
view at all. If the situation demands taking a risk, then
the physician should not be averse to taking it for fear of
being sued."
Peters does not know what tack the current situation
will tak~Reform in the legalsystem, more specific informed consent legislation, and better education of
physicians1 in training are being discussed. But regardless of
whether these measures are taken, the responsibility still
rests with the physician. According to Peters, physicians
owe it to their patients to describe all options, legal issues
notwithstanding. "We have to be bold enough to take
some risk if we're going to do the maximum good." ■

Physicians Treat Less Aggressively after Lawsuits
Peters' views are not simply based on subjective perception. A staff member of Peters' department, Neil Sherman,
M.D., recently conducted an anonymous survey of radiotherapists who had trained or worked at M. D. Anderson
at some point during the past 40 years. "He asked how
many had been sued-rightly or wrongly, justified or not.
He found that by the time the average radiotherapist had

Physicians who desire additional information may write Lester J.
Peters, M.D., Division of Radiotherapy, Box 97, The University of Texas
M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston,
Texas 77030, or call (713 ) 792-3411.
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Expandable Stents Provide Relief for Patients with
Tumor-compressed Tissue
Symptomatic palliation is an
important aspect of treating
terminally ill patients. The less
energy a patient has to spend
battling intense pain, the more
energy he or she can devote to
friends and family.
For the past several years,
M. D. Anderson Cancer Center
researchers have been investiC. Humberto Carrasco
gating the use of expandable
stents in cancer patients to palliate the symptoms caused
by compression of various tubular structures. The stent
was developed in 1984 by a former M. D. Anderson
physician, Cesare Gianturco, M.D., and is made of stainless-steel wire bent in a zig-zag. Using fluoroscopic
guidance, the stent is deployed in the desired location
through a catheter. In most cases, the stent then expands
and eliminates the obstruction (Figure 1 ).
Many physicians have participated in extensive laboratory investigation of the Gianturco stent at the John S.
Dunn Research Foundation Center for Radiological
Sciences. The foundation is based in the Department of
Diagnostic Radiology and is directed by Kenneth C.
Wright, Ph.D. Clinical investigations are being performed
by C. Humberto Carrasco, M.D., chief of the Section of
Angiography and Interventional Radiology. Carrasco and
his colleagues are currently using the stents, primarily in
lung cancer patients, to reestablish patency of compressed
vena cavas, trachea, bronchi, and bile ducts.

the stented structure. Thus, the risk of clot or debris being
deposited on the stent is reduced, " Carrasco said. "Another
advantage of the Gianturco stent is that it does not occlude
the orifices of side branches of stented vessels, bronchi, and
bile ducts."
Patients with compression of the vena cava may remain
asymptomatic if their collateral circulation is adequate.
Unfortunately, in many patients collateral circulation is
insufficient, and they develop painful swelling in the parts
of the body inadequately drained. In the case of superior
vena cava obstruction, increased venous pressure in the
brain leads to neurologic impairment. Of the 16 patients
with obstruction of the superior or inferior vena cava
treated with the Gianturco stent, symptoms were successfully palliated in 12, Carrasco said. "Interestingly, most
patients feel relief immediately after the stent is placed."

Inflammation Is Minor
The stent causes relatively minor inflammatory changes
in the tracheobronchial and biliary trees. "The stent elicits
mucosa! and endothelial proliferation, which eventually
covers its struts, essentially incorporating it into the wall of

Figure l. Hepatic segment of the inferior veno covo before (top) and ofter (bottom) plo_cement of
expandable wire "double" stent. The stent was placed ofter hepatic metastases from a melanoma hod
completely occluded the vein.
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Ten Patients Treated for Tracheobronchial
Obstructions

It is much better to inse~t the stent before occlusion,"
Carrasco said. Physicians considering referral of a patient for
relief of vena cava syndrome should do so as soon as possible.
"Waiting will only make symptoms worse," he said.
On the other hand, stenting of the tracheobronchial tree
is usually performed when the patient's symptoms become
severe. The bronchi usually have to be severely compressed
before the patient feels the effects, and irradiation alone may
palliate symptoms. Carrasco works closely with his colleagues in thoracic surgery and thoracic oncology, with
whom it is decided if stenting is indicated. "Bronchoscopy
needs to be performed first to determine the extent of the
tumor. If it extends into the lumen, the surgeon has to
decide whether laser ablation might reestablish patency.
The stent will probably not work if abundant intraluminal
tumor is present because it will grow right through the struts.
Stents are most effective when obstruction is due to extrinsic compression, and that is determined by bronchoscopy."

Carrasco has treated 10 patients with tracheobronchial
obstructions, six of whom were treated successfully. For
the most part, these patients had unresectable or untreatable advanced tumors. "This was a palliative measure, but
a very important one," he said. "Compression of the
trachea or bronchus makes breathing very difficult, so the
stent is very important for the comfort of these patients."
Carrasco is pleased-with the approximately 70% (18 of26)
success rate but considers these results only preliminary,
since the patient population is still small. Efforts are being
focused on why the stent is not always successful. "Our
biggest problem may be tumor that has previously been
irradiated. Radiotherapy controls the tumor but produces
scar tissue, " he said. T he reduced elasticity of scar tissue
requires a stent with more expansile force. "Eventually, we
should be able to calculate the expansile force needed in
each situation and use a stent that will exert the necessary
pressure to reestablish patency."

Biliary Use Recently Approved
Insertion of biliary stents is performed electively
because catheter drainage has to be established first. Recently, the Gianturco stent has been approved by the Food
and Drug Administration for use in obstructed bile ducts.
The M. D. Anderson experience with the biliary applications of the stent is somewhat limited; it has been more
extensively used at Sharp Memorial Hospital in San Diego
and in various European countries in a cooperative study.
It appears that the stent is more effective in patients with
benign biliary strictures than in those who have obstructions caused by tumors.
Other potential uses for the stent include the treatment
of unresectable aortic aneurysms, for which preliminary
animal studies have been promising. "Aneurysms have a
high incidence of rupture. Their primary treatment is
surgical, but in patients who are not surgical candidates,
the stent would be very useful." ■

Modified Stents No Longer Migrate
Aside from the few unsuccessful cases, Carrasco said the
problems have been few. "Early in our experience, we had
one case in which the stent migrated to the heart, where it
stayed for five months but did not cause any problems."
The stent has since been modified. Barbs have been added,
and two stents soldered together are now used in tandem.
"We now have much better control, and since that case,
no stents have migrated. In general, the stent's benefits far
outweigh the risks," Carrasco said.
Timing for stent insertion varies depending on the site.
"In patients with impending obstruction of a vena cava,
we prefer to insert the stent early. Once the obstruction
becomes complete, the resultant blood stasis may result in
clotting. Expansion of the compressed segment does not
accomplish much since the clot has already blocked blood
flow. Thus, the clot has to be dissolved first using thrombolytic agents, which increase the risk of complications.

Physicians who desire additional information may write C. Humberto
Carrasco, M.D., Division of Diagnostic Imaging, Box 57, The University
ofTexas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard
Houston, Texas 77030, or call (7 13 ) 792 -8295.
'
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Nutrition continued from page 8
"The problem with the amino acid formulas is that you
can't tinker with the eight essential amino acids because
then the normal tissues don't grow," Ota explained.
However, researchers have some latitude with the five
nonessenti.tl amino acids in a formula. "We can tinker with
those, make adjustments, and not affect normal tissue
anabolism. But these changes may affect tumor growth."

Another Formula Uses Glutamine
The gastrointestinal benefit of the other new formula O ta
has tried is important because cancer treatment regimens
can ravage the stomach lining and cause other gastrointesti nal tract problems through irritation or by killing gut flora.
In a handful of patients, Ota has tried protecting the
gastrointestinal tract by adding the nonessential amino acid
glutamine to commercial TPN formulas. The first patient
he did this for was a woman with short-gut syndrome. "She
was having repeated catheter infections," Ota said. "It
looked as if the infections were coming from her intestinal
tract and seeding on her catheter. I added the glutamine,
which, in theory, helps increase the gut mucosa! barrier to
bacteria. She hasn't had any infections since."

formula for cancer patients. In studies with male Fischer
344 rats with fibrosarcomas or colon tumors, the researchers found that polyamine synthesis increases in cancer cells
and that TPN formulas accelerate that synthesis. In the
animal studies, they used difluoromethylornithine (DFMO)
to selectively inhibit polyamine synthesis in tumor cells and
the nonessential amino acid ornithine to prevent the
thrombocytopenia associated with the drug. This amino
acid, also a polyamine precursor, appeared to selectively
stimulate polyamine synthesis in normal cells but did not
impede DFMO inhibition of this synthesis in tumor cells
(Cancer Research 49:4159, 1989).

"There has been a great deal of interest in glutamine,
which has not been a normal constituent of parenteral
formul~" Ota said. "The reason it's important is that
glutamine has a trophic effect on the intestinal tract."
Trauma patients should benefit from glutamine in their
TPN formulas, he said, because it could help protect the
gut mucosal barrier. The amino acid also could help
patients with ulcerative colitis or Crohn's disease, as well
as neonates, who have immature intestinal linings. "It also
may be very important to the cancer population, especially
those who are receiving chemotherapy, because one of the
side effects of chemotherapy is to destroy the lining of the
gastrointestinal tract," said Ota. He is working with other
M. D. Anderson researchers to design a randomized protocol for testing glutamine's effects on patients.

Changing the Nonessential Amino Acids
Because arginine seemed to favor tumor cell growth,
whereas ornithine does not, Ota and colleagues substituted
ornithine for arginine in the TPN solution that might be
used in cancer patients. For the ornithine-based formula,
"the experimental data show that it does not promote the
growth of tumors, and it appears to have a beneficial effect
on the intestinal tract," Ota said.
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Many of the cancer patients who receive TPN have
gastrointestinal tumors, Ota noted. And many patients who
receive TPN have advanced cancers. His own interest in
nutritional support research grew out of concern for his
gastrointestinal cancer patients. "I see these problems all the
time out on the inpatient floors and in the clinics; metastasis and malnutrition are major problems. Before they come
to treatment, a significant number of gastrointestinal cancer
patients have a history of weight loss," he added.
"What can we d o for these patients? We try to get them
on therapy as quickly as possible to control their disease. If
you get control of the growth of metastatic cancer, patients
will start to do better, to eat and to feel better. You have to
get control of the tumor growth. If you don't, even the
hyperalimentation doesn't help."

Editor

Contributing Editor

Kevin Flynn

Mory Markell

Art and Photography

Monico Keogh, Design and Layout
Donald G. Kelley, Photographs
Editorial Board

David M.Gershenson, M.D.; Frankie A. Holmes, M.D.; Raymond E. Meyn, Jr., Ph.D.;
William K.Plunkett, Jr., Ph.D.; TyvinA. Rich, M.D.; S. Eva Singletary, M.D.;
Michael J. Worgovich, Ph.D.
Published quarterly by the Deportment of Scientific Publications, Division of
Academic Affairs, The University of Texos M. D.Anderson Cancer Center,
1515 Holcombe Boulevard, Houston, Texas 77030.
Mode possible by ogift from the late Mrs. Horry C. Wiess.

tissues," he said. "That's why I don't feel justified in giving
patients the TPN formulas unless they are receiving active,
ongoing cancer therapy."
Sometimes, though, TPN represents hope to a terminally
ill patient. "I have sent patients home on TPN who were
terminally ill. To cut them off would mean no hope; they
would feel abandoned. But by and large, I am not supportive of sending people home on TPN when they are not
on active therapy.
"This specialized area nutrition [TPN] for the cancer
population-is really in its infancy," Ota summed up.
"People have searched long and hard for better formulas.
But we're just starting to come up with new formulas that
address tumor growth and the recovery of the gut mucosa!

Total Parenteral Nutrition Can Be a Doubleedged Sword
Ota believes that nutritional support should be just
that-support for patients undergoing active therapy. TPN
for advanced cancer patients "is a double-edged sword. It's
a question of who's going to win out for the nutrientstumor or normal cells. If you can knock out cancer cells
with chemotherapy, surgery, or radiation therapy, the
remaining tumor cells don't consume as much of the
available nutrients. Then the tide shifts over to the normal

lining." ■

Physicians who desire additional information may write David Ota,
M.D., Department of General Surgery, Box 106, The University of Texas
M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston,
Texas 77030, or call (713 ) 792-7216.
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Total Parenteral Nutrition: The Double-edged Sword
formula in tigational ne drug tatu
clinical trial in motion. ntil th n th
gi n to pati nts.

Nutritional support aimed at
sustaining cancer patients often
contributes to tumor growth, an
M. D. Anderson Cancer Center
team has found. After years of
laboratory work, these ph sicians ha e found what they hop
is a solution-a total parenteral
nutrition (TP ) pr paration
based on a new formula the
David Oto
believe will eliminate the cancer
cells' ad antage in the competition for nutrients. In addition, they believe that the new formula, as well as a further
variation on the amino acid feeding solutions, will pre ent
some drug- or tumor-caused gastrointestinal problems.
"We're trying to de elop an amino acid formula that does
not stimulate the growth rate of tumors compared with
standard commercial formulas," said David Ota, M.D.,
deputy chairman of the Department of General Surgery. He
and his colleagues have developed the first TP formula
specifically for cancer patients; they ha e applied for a patent
and hope the Food and Drug Administration will give the
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Normal Cells Must Compete with Cancer Cell
for Nutrients
"Th ba ic pro bl m [ in TP ] Ota e plain
cane r c 11 and normal c 11
mp t f◄ r th
m
ents. If ou gi
om n nutriti nal th rap , it
tion of ho' going to win thi
mp titi n.
m tudi
indicate that nutritional th rap v ·th ut ntr 1 f tu m r
growth actuall lead to arli r p ti nt d th. Thi m an
ou're fe ding the twnor and it pr gr
until th
patient dies."
Ota, along with Kenji i hioka Ph.D. and . Bru
Grossie, Ph.D. of the Department of G n ral ur
and
Jaffer A. Ajani M.D. of the Department of 1 di al
Oncology, has tracked the problem of TP - nhan d
tumor growth to the nonessential amino a id and pol amine precursor that man total parenteral olution ar ba ed
on-arginine-and applied their finding to de ignin a
continued on page 6
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